Comprehensive analysis of the RSK gene family in acute myeloid leukemia determines a prognostic signature for the prediction of clinical prognosis and treatment responses

References

• Thomas D, Majeti R. Biology and relevance of human acute myeloid leukemia stem cells. Blood. 2017;129(12):1577–1585.
   PubMed Web of Science ®Google Scholar
• Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib or chemotherapy for relapsed or refractory flt3-mutated aml. N Engl J Med. 2019;381(18):1728–1740.
   PubMed Web of Science ®Google Scholar
• Stein EM, DiNardo CD, Pollyea DA, et al. Enasidenib in mutant idh2 relapsed or refractory acute myeloid leukemia. Blood. 2017;130(6):722–731.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Stein EM, de Botton S, et al. Durable remissions with ivosidenib in idh1-mutated relapsed or refractory aml. N Engl J Med. 2018;378(25):2386–2398.
   PubMed Web of Science ®Google Scholar
• Vago L, Gojo I. Immune escape and immunotherapy of acute myeloid leukemia. J Clin Invest. 2020;130(4):1552–1564.
   PubMed Web of Science ®Google Scholar
• Candon D. The effect of cancer on the labor supply of employed men over the age of 65. Econ Hum Biol. 2018;31:184–199.
   PubMed Web of Science ®Google Scholar
• Ram R, Amit O, Zuckerman T, et al. Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents-a multicenter historical prospective study. Ann Hematol. 2019;98(8):1927–1932.
   PubMed Web of Science ®Google Scholar
• Estey EH. Acute myeloid leukemia: 2019 update on risk-stratification and management. Am J Hematol. 2018;93(10):1267–1291.
   PubMed Web of Science ®Google Scholar
• Shallis RM, Wang R, Davidoff A, et al. Epidemiology of acute myeloid leukemia: recent progress and enduring challenges. Blood Rev. 2019;36:70–87.
   PubMed Web of Science ®Google Scholar
• Zhang L, Ke W, Hu P, et al. N6-methyladenosine-related lncrnas are novel prognostic markers and predict the immune landscape in acute myeloid leukemia. Front Genet. 2022;13:804614.
   PubMed Web of Science ®Google Scholar
• Fu D, Zhang B, Wu S, et al. Prognosis and characterization of immune microenvironment in acute myeloid leukemia through identification of an autophagy-related signature. Front Immunol. 2021;12:695865.
   PubMed Web of Science ®Google Scholar
• Jones SW, Erikson E, Blenis J, et al. A xenopus ribosomal protein s6 kinase has two apparent kinase domains that are each similar to distinct protein kinases. Proc Natl Acad Sci USA. 1988;85(10):3377–3381.
   PubMed Web of Science ®Google Scholar
• Fisher TL, Blenis J. Evidence for two catalytically active kinase domains in pp90rsk. Mol Cell Biol. 1996;16(3):1212–1219.
   PubMed Web of Science ®Google Scholar
• Powell BL, Moser B, Stock W, et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American leukemia intergroup study c9710. Blood. 2010;116(19):3751–3757.
   PubMed Web of Science ®Google Scholar
• Soignet SL, Frankel SR, Douer D, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol: Off J American Soc Clin Oncol. 2001;19(18):3852–3860.
   PubMed Web of Science ®Google Scholar
• Parmar S, Rundhaugen LM, Boehlke L, et al. Phase ii trial of arsenic trioxide in relapsed and refractory acute myeloid leukemia, secondary leukemia and/or newly diagnosed patients at least 65 years old. Leuk Res. 2004;28(9):909–919.
   PubMed Web of Science ®Google Scholar
• Galvin JP, Altman JK, Szilard A, et al. Regulation of the kinase rsk1 by arsenic trioxide and generation of antileukemic responses. Cancer Biol Ther. 2013;14(5):411–416.
   PubMed Web of Science ®Google Scholar
• Watanabe D, Nogami A, Okada K, et al. Flt3-itd activates rsk1 to enhance proliferation and survival of aml cells by activating mtorc1 and eif4b cooperatively with pim or pi3k and by inhibiting bad and bim. Cancers (Basel). 2019;11(12).
   Web of Science ®Google Scholar
• Li Z, Herold T, He C, et al. Identification of a 24-gene prognostic signature that improves the European leukemianet risk classification of acute myeloid leukemia: an international collaborative study. J Clin Oncol: Off J American Soc Clin Oncol. 2013;31(9):1172–1181.
   PubMed Web of Science ®Google Scholar
• Herold T, Metzeler KH, Vosberg S, et al. Isolated trisomy 13 defines a homogeneous aml subgroup with high frequency of mutations in spliceosome genes and poor prognosis. Blood. 2014;124(8):1304–1311.
   PubMed Web of Science ®Google Scholar
• Kuett A, Rieger C, Perathoner D, et al. Il-8 as mediator in the microenvironment-leukaemia network in acute myeloid leukaemia. Sci Rep. 2016;5:18411.
   Web of Science ®Google Scholar
• Herold T, Jurinovic V, Batcha AMN, et al. A 29-gene and cytogenetic score for the prediction of resistance to induction treatment in acute myeloid leukemia. Haematologica. 2018;103(3):456–465.
   PubMed Web of Science ®Google Scholar
• Metzeler KH, Hummel M, Bloomfield CD, et al. An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia. Blood. 2008;112(10):4193–4201.
   PubMed Web of Science ®Google Scholar
• Wagner GP, Kin K, Lynch VJ. Measurement of mrna abundance using RNA-Seq data: Rpkm measure is inconsistent among samples. Theory in Biosciences = Theorie in den Biowissenschaften. 2012;131(4):281–285.
   PubMed Web of Science ®Google Scholar
• Chandrashekar DS, Bashel B, Balasubramanya SAH, et al. Ualcan: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia (New York, NY). 2017;19(8):649–658.
   PubMed Web of Science ®Google Scholar
• Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of aml in adults: 2017 eln recommendations from an international expert panel. Blood. 2017;129(4):424–447.
   PubMed Web of Science ®Google Scholar
• Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-Seq data with deseq2. Genome Biol. 2014;15(12):550.
   PubMed Web of Science ®Google Scholar
• Yu G, Wang LG, Han Y, et al. Clusterprofiler: an r package for comparing biological themes among gene clusters. Omics: A J Integr Biol. 2012;16(5):284–287.
   PubMed Web of Science ®Google Scholar
• Maeser D, Gruener RF, Huang RS. Oncopredict: an r package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data. Brief Bioinform. 2021;22(6):bbab260.
   PubMed Web of Science ®Google Scholar
• Geeleher P, Cox N, Huang RS. Prrophetic: an r package for prediction of clinical chemotherapeutic response from tumor gene expression levels. PloS one. 2014;9(9):e107468.
   PubMed Web of Science ®Google Scholar
• Szklarczyk D, Gable AL, Lyon D, et al. String v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res 2019;47(D1):D607–D613.
   PubMed Web of Science ®Google Scholar
• Goldman SL, Hassan C, Khunte M, et al. Epigenetic modifications in acute myeloid leukemia: prognosis, treatment, and heterogeneity. Front Genet. 2019;10:133.
   PubMed Web of Science ®Google Scholar
• Gores GJ, Kaufmann SH. Selectively targeting Mcl-1 for the treatment of acute myelogenous leukemia and solid tumors: Figure 1. Genes Dev. 2012;26(4):305–311.
   PubMed Web of Science ®Google Scholar
• Czabotar PE, Lessene G, Strasser A, et al. Control of apoptosis by the bcl-2 protein family: Implications for physiology and therapy. Nat Rev Mol Cell Biol. 2014;15(1):49–63.
   PubMed Web of Science ®Google Scholar
• Mitton B, Hsu K, Dutta R, et al. Small molecule screen for inhibitors of expression from canonical creb response element-containing promoters. Oncotarget. 2016;7(8):8653–8662.
   PubMedGoogle Scholar
• Mizutani Y, Inase A, Maimaitili Y, et al. An mtorc1/2 dual inhibitor, azd2014, acts as a lysosomal function activator and enhances gemtuzumab ozogamicin-induced apoptosis in primary human leukemia cells. Int J Hematol. 2019;110(4):490–499.
   PubMed Web of Science ®Google Scholar
• Meja K, Stengel C, Sellar R, et al. Pim and akt kinase inhibitors show synergistic cytotoxicity in acute myeloid leukaemia that is associated with convergence on mtor and mcl1 pathways. Br J Haematol 2014;167(1):69–79.
   PubMed Web of Science ®Google Scholar
• Lawal B, Kuo YC, Khedkar H, et al. Deciphering the immuno-pathological role of flt, and evaluation of a novel dual inhibitor of topoisomerases and mutant-flt3 for treating leukemia. Am J Cancer Res. 2022;12(11):5140–5159.
   PubMed Web of Science ®Google Scholar
• Liu H, Hussain Z, Xie Q, et al. Targeting pi3k/akt/mtor pathway to enhance the anti-leukemia efficacy of venetoclax. Exp Cell Res. 2022;417(2):113192.
   PubMed Web of Science ®Google Scholar